Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP Shirley R. Kuhlmann sold 26,067 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $28.50, for a total transaction of $742,909.50. Following the transaction, the executive vice president now owns 108,137 shares in the company, valued at approximately $3,081,904.50. The trade was a 19.42 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Collegium Pharmaceutical Trading Up 4.7 %
Shares of COLL opened at $29.80 on Friday. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 52-week low of $27.28 and a 52-week high of $42.29. The firm has a market cap of $938.28 million, a price-to-earnings ratio of 12.84 and a beta of 0.99. The business's fifty day moving average is $30.78 and its 200-day moving average is $33.28.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. The firm had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
COLL has been the subject of several recent research reports. Piper Sandler cut their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research note on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 target price for the company in a research report on Friday, January 10th. Finally, HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $43.60.
Check Out Our Latest Research Report on COLL
Hedge Funds Weigh In On Collegium Pharmaceutical
Several institutional investors and hedge funds have recently added to or reduced their stakes in COLL. Invesco Ltd. increased its holdings in shares of Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock worth $50,876,000 after buying an additional 289,335 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock worth $67,459,000 after purchasing an additional 64,958 shares in the last quarter. Renaissance Technologies LLC raised its position in Collegium Pharmaceutical by 0.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock valued at $47,603,000 after purchasing an additional 5,480 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company's stock valued at $29,974,000 after purchasing an additional 5,464 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in Collegium Pharmaceutical by 17.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company's stock valued at $29,586,000 after acquiring an additional 116,327 shares during the period.
About Collegium Pharmaceutical
(
Get Free Report)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
